小细胞肺癌因染色体外DNA扩增MYC旁系同源基因获得交叉耐药
研究基于51例患者来源异种移植模型,在体内测试三种临床方案,发现早期复发后出现治疗难治性疾病;系列模型显示交叉耐药通过染色体外DNA上的MYC扩增获得,MYC旁系同源基因扩增在复发交叉耐药小细胞肺癌中反复出现,并在复发患者活检中佐证。
要点
- 51例PDX模型体内测试顺铂联合依托泊苷、奥拉帕利联合替莫唑胺和拓扑替康三种方案。
- 系列PDX模型显示交叉耐药通过染色体外DNA上的MYC扩增获得。
- MYC旁系同源基因的ecDNA扩增在复发交叉耐药小细胞肺癌中反复出现。
核心结论
- 携带MYC旁系同源基因的染色体外DNA是小细胞肺癌交叉耐药的反复驱动因素。
研究设计与样本
- 临床前系统,基于51例患者来源异种移植模型,每个模型在体内测试三种临床方案:顺铂联合依托泊苷、奥拉帕利联合替莫唑胺和拓扑替康。
主要发现
- 药物反应谱再现了小细胞肺癌的临床特征,如早期复发后出现治疗难治性疾病。
- 对一例患者的系列PDX模型显示交叉耐药通过染色体外DNA上的MYC扩增获得。
- 全PDX面板的基因组和转录谱显示MYC旁系同源基因的ecDNA扩增在复发交叉耐药小细胞肺癌中反复出现,并在复发患者肿瘤活检中佐证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients but has been difficult to capture in laboratory models. Here, we present a preclinical system that recapitulates acquired cross-resistance, developed from 51 patient-derived xenograft (PDX) models. Each model was tested in vivo against three clinical regimens: cisplatin plus etoposide, olaparib plus temozolomide, and topotecan. These drug-response profiles captured hallmark clinical features of SCLC, such as the emergence of treatment-refractory disease after early relapse. For one patient, serial PDX models revealed that cross-resistance was acquired through MYC amplification on extrachromosomal DNA (ecDNA). Genomic and transcriptional profiles of the full PDX panel revealed that MYC paralog amplifications on ecDNAs were recurrent in relapsed cross-resistant SCLC, and this was corroborated in tumor biopsies from relapsed patients. We conclude that ecDNAs with MYC paralogs are recurrent drivers of cross-resistance in SCLC. SIGNIFICANCE: SCLC is initially chemosensitive, but acquired cross-resistance renders this disease refractory to further treatment and ultimately fatal. The genomic drivers of this transformation are unknown. We use a population of PDX models to discover that amplifications of MYC paralogs on ecDNA are recurrent drivers of acquired cross-resistance in SCLC. This article is featured in Selected Articles from This Issue, p. 695.
引用
- Pal Choudhuri S, Girard L, Lim JYS, et al. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs. Cancer Discov. 2024. PMID: 38386926. doi:10.1158/2159-8290.CD-23-0656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。